Bioreductive anticancer agent; selectively toxic to cells under hypoxic conditions. Prepn: R. F. Robbins, K. Schofield, J. Chem. Soc. 1957, 3186; J. C. Mason, G. Tennant, J. Chem. Soc. B 1970, 911. See also: K. Ley et al., DE 2204574; eidem, US 3868371 (1973, 1975 both to Bayer). HPLC determn in plasma: H. Robin, Jr. et al., Cancer Chemother. Pharmacol. 36, 266 (1995). Review of pharmacology and mechanism of action studies: J. M. Brown, Br. J. Cancer 67, 1163-1170 (1993). Clinical evaluation in combination with cisplatin: C. A. Johnson et al., J. Clin. Oncol. 15, 773 (1997).
Antineoplastic.
Antineoplastic